Covid-19
New COVID-19 drug gets US approval
The United States of America has given approval for the use of Remdesivir, a new drug, to treat Coronavirus patients in the country.
President Donald Trump who disclosed this at the weekend explained that the drug which is manufactured by American pharmaceutical company, Gilead Sciences, showed that patients who took it recovered within eleven days during its trial testing.
Gilead Sciences’ Chief Executive Officer, Daniel O’Day, who was present during Trump’s live announcement, used the occasion “to thank the collaborators that brought remdesivir to this point and many of our people that have ben part of this, in fact, the caregivers”.
He also stated that the company will be donating 1.5 million vials of the intravenous drug.
The emergency use authorisation for remdesivir does not mean that the drug has been given express approval by America’s Food and Drug Administration, FDA. As a matter of fact, the drug has not undergone any thorough review that would then give it the appropriate approval to treat patients. However, doctors can use it to treat patients for now due to the emergency nature of the Coronavirus pandemic.
Researchers have, however, pointed out that remdesivir’s side effects could be as mild as nausea and vomiting, or as severe as liver damage.
Recall that this is not the first time President Trump has been too eager to present a drug as a cure for the deadly virus. Recall that in March, Trump announced that the FDA approved the malaria drug – Chloroquine – as a cure for COVID-19. The FDA later faulted this claim.
-
Latest1 week agoLagos NURTW organising secretary Toba Ajiboye dies after gunmen attack
-
Business5 days agoCBN targets $12bn annual Diaspora inflows to boost FX liquidity
-
Business5 days agoSEC launches nationwide campaign to help investors recover unclaimed dividends
-
Business4 days agoNigerian AI researcher champions ethical artificial intelligence at COPA AI 2026 summit in Wales
-
Latest1 week agoOyo APC berates Makinde over call for UN probe into Oriire school rescue
-
Business5 days agoCBN launches real-time FX tracker for BDCs, tightens oversight of FX market
-
Business5 days agoFood prices now biggest threat to inflation, beyond CBN’s reach – Analysts
-
Latest6 days agoKwankwaso calls for renewed North–South-East Political alliance ahead of 2027


